Department of Neurology, UMC Utrecht Stroke Centre, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The Netherlands.
Eur J Pharmacol. 2013 Nov 5;719(1-3):153-160. doi: 10.1016/j.ejphar.2013.04.055. Epub 2013 Jul 17.
This paper appears in a special issue of the European Journal of Pharmacology that commemorates the retirement of Professor Willem Hendrik Gispen as distinguished professor of Utrecht University and as editor of the European Journal of Pharmacology. The paper provides an overview of a research line on the impact of diabetes on cognition that we started together 20 years ago, and that continues to this day. I will report how we more or less stumbled upon this topic, that was understudied, but proved to be of definite clinical relevance. I will discuss how we tried to establish animal models, how developments from clinical and experimental studies from around the world led us to reconsider our concepts, and how findings from research on diabetic neuropathy, insulin signaling in the brain, Alzheimer's disease and dementia, and vascular disease and stroke converged and helped to create new ideas and refute others. This voyage has not ended yet, because the ultimate goal is to offer patients with diabetes treatment that can protect them against accelerated cognitive decline. Although this could take another 20 years, the research from Willem Hendrik and his group brought us an important step in the right direction.
本文发表在《欧洲药理学杂志》的一个特刊上,以纪念 Willem Hendrik Gispen 教授从乌得勒支大学荣休,并纪念他担任《欧洲药理学杂志》编辑。本文概述了我们 20 年前开始的、关于糖尿病对认知影响的研究,这一研究至今仍在继续。我将报告我们是如何或多或少偶然地开始研究这个课题的,这个课题以前研究较少,但证明具有明确的临床相关性。我将讨论我们如何试图建立动物模型,来自世界各地的临床和实验研究的进展如何促使我们重新考虑我们的概念,以及糖尿病性神经病、大脑中的胰岛素信号、阿尔茨海默病和痴呆症以及血管疾病和中风方面的研究结果如何汇聚并帮助创造新的理念和反驳其他理念。这一探索尚未结束,因为最终目标是为糖尿病患者提供能够防止认知能力加速下降的治疗方法。虽然这可能还需要 20 年的时间,但 Willem Hendrik 及其团队的研究为我们朝着正确的方向迈出了重要的一步。